archive

• December 13, 2006 - Analysis by AlgoNomics reveals that Anticalins intrinsically have an immunogenicity level comparable to the wild-type human lipocalin
• October 25, 2006 - Pieris confirms in vivo activity of potent VEGF specific Anticalin
• September 27, 2006 - Crystallographic analysis of Anticalin targeting CTLA-4 confirms the excellent suitability of Pieris’ lipocalin scaffold to develop superior biotherapeutics
• July 6, 2006 - Pieris reaches key milestones under the collaboration agreement with Syngenta
• June 21, 2006 - Pieris appoints Dr Andreas Hohlbaum as member of its management team 
• May 17, 2006 - Pieris appoints new Chief Executive Officer
• April, 21, 2006 - Pieris enters into a collaborative research and option agreement with GE Healthcare
• April 13, 2005 - Pieris Proteolab AG and Syngenta Biopharma collaborate to develop Anticalins 
• March 10, 2004 - In vivo proof of concept for Anticalins
• May 7, 2004 - Pieris receives € 2 million grant from German Ministry of Education and Research (BMBF) 
• September 15, 2004 - Prof Arne Skerra, Dr Martin Pöhlchen and Dr Steffen Schlehuber nominated for the German Future Prize (Deutscher Zukunftspreis) 2004 of the German Federal President
• July 24, 2003 - Pieris Proteolab AG and Technical University of Munich announce strategic alliance in Anticalin research
• November 18, 2003 - Pieris announces breakthrough in Anticalin technology
• January 24, 2002 - Pieris and CytoTools sign R&D collaboration agreement for the development of Anticalins against novel targets in atherosclerosis
• October 31, 2002 - Pieris Proteolab AG closes € 12 million financing round  
• July 19, 2001 - Pieris Proteolab AG appoints Chief Executive Officer
• October 23, 2001 - Pieris wins award in the fifth round of the Biochance competition 
• November 5, 2001 - Pieris wins award during Biotech & Finance Conference in Paris
• November 13, 2001 - Pieris releases human Anticalin library with more than 10 billion structures